ChiCTR2600126552 版本V1.0 版本创建时间2026/06/11 09:44:10 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2600126552 

最近更新日期:

Date of Last Refreshed on:

2026-06-11 09:43:55 

注册时间:

Date of Registration:

2026-06-11 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

肺癌化疗患者疲乏相关症状群干预方案的构建和应用

Public title:

Development and Application of an Intervention Program for Fatigue-Related Symptom Clusters in Lung Cancer Patients Undergoing Chemotherapy

注册题目简写:

English Acronym:

研究课题的正式科学名称:

肺癌化疗患者疲乏相关症状群干预方案的构建和应用

Scientific title:

Development and Application of an Intervention Program for Fatigue-Related Symptom Clusters in Lung Cancer Patients Undergoing Chemotherapy

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

于晴 

研究负责人:

仓顺东 

Applicant:

Yu Qing 

Study leader:

Cang Shundong 

申请注册联系人电话:

Applicant telephone:

+86 15139490887

研究负责人电话:

Study leader's
telephone:

+86 371 87160147

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

2090842046@qq.com

研究负责人电子邮件:

Study leader's E-mail:

cangshundong@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

河南省郑州市金水区纬五路河南省人民医院

研究负责人通讯地址:

河南省郑州市金水区纬五路7号

Applicant address:

Zhongyuan District, Zhengzhou City, Henan Province - Zhengzhou University

Study leader's address:

7 Weiwu Road, Jinshui District, Zhengzhou, Henan, China.

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

河南省人民医院

Applicant's institution:

Henan Provincial People's Hospital

研究负责人所在单位:

河南省人民医院

Affiliation of the Leader:

Henan Provincial People's Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

(2026)伦审第(67)号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

河南省人民医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Henan Provincial People's Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2026-04-09 00:00:00

伦理委员会联系人:

张辉

Contact Name of the ethic committee:

Hui Zhang

伦理委员会联系地址:

河南省郑州市金水区纬五路7号

Contact Address of the ethic committee:

7 Weiwu Road, Jinshui District, Zhengzhou, Henan, China.

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 371 87160680

伦理委员会联系人邮箱:

Contact email of the ethic committee:

hnsrmyyzh@126.com

研究实施负责(组长)单位:

河南省人民医院

Primary sponsor:

Henan Provincial People's Hospital

研究实施负责(组长)单位地址:

河南省郑州市金水区纬五路7号

Primary sponsor's address:

7 Weiwu Road, Jinshui District, Zhengzhou, Henan, China.

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

河南省

市(区县):

Country:

China

Province:

Henan

City:

单位(医院):

河南省人民医院

具体地址:

河南省郑州市金水区纬五路7号

Institution
hospital:

Henan Provincial People's Hospital

Address:

7 Weiwu Road, Jinshui District, Zhengzhou, Henan, China.

经费或物资来源:

自选课题(自筹)

Source(s) of funding:

Self-selected topic (self-funded)

研究疾病:

肺癌化疗患者疲乏相关症状群  

Target disease:

Symptom cluster related to fatigue in patients undergoing chemotherapy for lung cancer

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

整群随机分组 

Study design:

Cluster randomization 

研究目的:

构建肺癌化疗患者疲乏相关症状群的干预方案并探讨疲乏相关症状群干预方案在肺癌化疗患者中的应用效果,帮助肺癌化疗患者改善症状体验,提高生存质量。  

Objectives of Study:

Develop an intervention plan for the fatigue-related symptom cluster in lung cancer chemotherapy patients and explore the application effect of this intervention plan in lung cancer chemotherapy patients. This will help lung cancer chemotherapy patients improve their symptom experience and enhance their quality of life.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.年龄≥18 周岁; 2.经病理和细胞学检查明确诊断为原发性 非小细胞肺癌,且病情稳定; 3.接受化学治疗; 4.意识清晰,有独立沟通能力; 5.存在疲乏相关症状群中至少 2 种症状(使用 NRS 量表评估且评分≥2 分, 患者报告过去一周存在疲乏或睡眠障碍); 6.均自愿参加本研究。

Inclusion criteria

1. Age >= 18 years old; 2. Diagnosed as primary non-small cell lung cancer through pathological and cytological examinations, and the condition is stable; 3. Undergoing chemotherapy; 4. Clear consciousness, capable of independent communication Force; 5. There were at least 2 symptoms related to fatigue (assessed using the NRS scale and with a score of ≥ 2, indicating that the patients reported experiencing fatigue or sleep disorders in the past week); 6. All participants voluntarily participated in this study.

排除标准:

1.肺癌复发或远处脏器转移; 2.合并放疗、免疫治疗、靶向 治疗等其他治疗方式; 3.合并各种重要脏器严重疾病; 4.正在参与其他类似 研究。

Exclusion criteria:

1. Recurrence of lung cancer or distant organ metastasis; 2. Concurrent with other treatment modalities such as radiotherapy, immunotherapy, and targeted therapy; 3. Concurrent with various serious diseases of important organs; 4. Currently participating in other similar studies.

研究实施时间:

Study execute time:

From 2026-06-15 00:00:00 To 2027-07-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-06-15 00:00:00 To 2027-07-01 00:00:00

干预措施:

Interventions:

组别:

对照组

样本量:

34

Group:

control group

Sample size:

干预措施:

常规护理

干预措施代码:

Intervention:

usual care

Intervention code:

组别:

试验组

样本量:

34

Group:

Experimental group

Sample size:

干预措施:

肺癌化疗患者疲乏相关症状群干预方案

干预措施代码:

Intervention:

Intervention Program for Fatigue-related Symptoms in Patients with Lung Cancer Undergoing Chemotherapy

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

河南省 

市(区县):

 

Country:

China

Province:

Henan

City:

单位(医院):

河南省人民医院 

单位级别:

三级甲等 

Institution
hospital:

Henan Provincial People's Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

疼痛数字评定量表

指标类型:

主要指标

Outcome:

Numerical Rating Scale, NRS

Type:

Primary indicator

测量时间点:

干预前、干预后、干预后 1 个月

测量方法:

问卷调查法

Measure time point of outcome:

Before the intervention, after the intervention, one month after the intervention

Measure method:

questionnaire survey

指标中文名:

中文版简明疲劳量表

指标类型:

主要指标

Outcome:

Chinese version Brief Fatigue Inventory, BFI-C

Type:

Primary indicator

测量时间点:

干预前、干预后、干预后 1 个月

测量方法:

问卷调查法

Measure time point of outcome:

Before the intervention, after the intervention, one month after the intervention

Measure method:

questionnaire survey

指标中文名:

癌症自我管理效能感量表

指标类型:

次要指标

Outcome:

Strategies Used by People to Pro‐mote Health, SU PHH

Type:

Secondary indicator

测量时间点:

干预前、干预后、干预后 1 个月

测量方法:

问卷调查法

Measure time point of outcome:

Before the intervention, after the intervention, one month after the intervention

Measure method:

questionnaire survey

指标中文名:

匹兹堡睡眠质量指数量表

指标类型:

主要指标

Outcome:

Pittsburgh Sleep Quality Index, PSQI

Type:

Primary indicator

测量时间点:

干预前、干预后、干预后 1 个月

测量方法:

问卷调查法

Measure time point of outcome:

Before the intervention, after the intervention, one month after the intervention

Measure method:

questionnaire survey

指标中文名:

肺癌患者生存质量测定量表

指标类型:

次要指标

Outcome:

Functional Assessment of Cancer Therapy- Lung, FACT-L

Type:

Secondary indicator

测量时间点:

干预前、干预后、干预后 1 个月

测量方法:

问卷调查法

Measure time point of outcome:

Before the intervention, after the intervention, one month after the intervention

Measure method:

questionnaire survey

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

NA

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

为避免出现沾染,采取抛硬币法确定一个病区为对照组,另一个病区为干预组。 两个病区收治的患者来源无差异,治疗及用药均符合肺癌诊治指南,患者一般资 料、 医护人员构成相差不大。

Randomization Procedure (please state who generates the random number sequence and by what method):

To avoid contamination, a coin toss was used to randomly assign one ward as the control group and the other as the intervention group. Patients admitted to both wards were similar in source, and treatment and medication followed lung cancer diagnosis and treatment guidelines. There were no significant differences in patient demographics or healthcare staff composition between the two wards.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

开放标签

Blinding:

Open-label study

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

不共享

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Not shared

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

纸质病历记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form, CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2026-06-11 09:43:55